Understanding the Immunological Strategy: What Is the Mechanism of Action of AMG 757?
•
4 min read
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with high relapse rates and poor prognosis. The investigational immunotherapy AMG 757, also known as tarlatamab, utilizes a novel bispecific T-cell engager (BiTE) technology to combat this disease by harnessing the patient's own immune system.
